AIM: To analyze clinical observation and the efficiency of intravitreal conbercept combined with 532-laser on Coats disease in adulthood.

METHODS: This was an retrospective analysis. Six eyes from 6 patients(5 males and 1 female)with coats disease diagnosed by fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were enrolled. Before the injection, best-corrected visual acuity(BCVA)of early treatment of diabetic retinopathy study(ETDRS), non-contact tonometer, ophthalmoscope, fundus photography, FFA, and OCT were examined. The initial average visual acuity(ETDRS letters)were 51.17±15.15. The initial average central retina thickness(CRT)was 303.30±107.87μm. All affected eyes were treated with intravitreal conbercept 0.05mL(10mg/mL)combined with 532-laser. Patients were followed up for 6 to 12mo, with a mean duration of 7.33±1.26mo. Post-treatment BCVA were compared with baseline using repeat analysis.

RESULTS: The mean BCVA showed significant improvement during 1 wk, 1, 3mo post-treatment and the latest follow up(P<0.01). During the latest follow up, the mean BCVA was obviously improved in 3 eyes(50%), improved in 2 eyes(40%), stable in 1 eyes(10%). Likewise, the subretina fluid absorption of different levels. No adverse events such as secondary retinal detachment or endophthalmitis were found during the follow-up.

CONCLUSION: Coats disease in adulthood more likely to have lower symptom and have a better response on treatment. Intravitreal conbercept combined with 532-laser significantly improve visual acuity and absorb the subretina fluid.